Quantum Genomics announced results of the Phase IIb QUORUM study were presented by Prof. Gilles Montalescot (Paris) on August 27, 2021 during the 2021 scientific sessions of the European Society of Cardiology (ESC). Highlights from the phase IIb QUORUM study are included below: Better efficacy of firibastat than ramipril in severe patients; 295 patients were enrolled in the study within 24 hours of a first myocardial infarction. After 12 weeks of treatment, the left ventricular ejection fraction evaluated by cardiac MRI, increased from 53 to 59% in the firibastat 100 mg twice daily group, from 51 to 58% in the firibastat 500 mg twice daily group and 50 to 57% in the ramipril 5 mg twice daily control group; these strata encompassing the entire study population. The difference between the 3 groups was not statistically significant. In the subgroup of severe patients with an ejection fraction less than 50%, the ejection fraction increased by 5.32 ± 1.67% under firibastat 500 mg, and by 3.51 ± 1.64% under ramipril. Only firibastat improved the patients' blood pressure profile, especially in severe patients; Blood pressure did not limit increasing doses of firibastat to reach the target dose, while 32.5% of patients failed to reach the target dose with ramipril. Good safety profile: Firibastat was safe and well tolerated. The most common side effects were skin reactions, which occurred in 4% of cases with firibastat 100 mg BID, 10% with firibastat 500 mg BID and 5% with ramipril (including angioedema, a well-known potentially severe side effect of ramipril). Renal impairment or hyperkalemia has not been observed with firibastat.